Menu

FDA OKs Clinical Trials of Ecstasy for PTSD

The illicit drug has shown promise in helping people with debilitating post-traumatic stress disorder.

Dec 1, 2016
Joshua A. Krisch

MDMAWIKIMEDIA, USDOJThe US Food and Drug Administration (FDA) has given the green light for Phase 3 clinical trials to test whether MDMA, an illegal drug also known as Ecstasy, can help treat post-traumatic stress disorder in a trial with at least 230 participants. This large-scale study comes on the heels of six promising Phase 2 trials of MDMA.

“I’m cautious but hopeful,” Charles Marmar, a psychiatrist at New York University’s Langone School of Medicine who was not involved in the study, told The New York Times. “If they can keep getting good results, it will be of great use. PTSD can be very hard to treat. Our best therapies right now don’t help 30 to 40 percent of people.”

Psychiatrists have been interested in exploiting the euphoric effects of MDMA in the clinic since the 1970s, but once Ecstasy was swept up in the Drug Enforcement Act’s crackdown on illegal substances, its Schedule 1 status prevented most research. In recent years, restrictions have loosened, and at least one promising study has shown that just three doses of MDMA administered by a psychiatrist may decrease PTSD symptoms by 56 percent, on average. In light of these results, researchers have applied for a Breakthrough Therapy Designation with the FDA, which could speed up the review process, the New York Times noted.

Not all physicians are convinced that MDMA is a safe for research, and some have expressed concern that widespread use of MDMA could kick-start another drug abuse epidemic. “It sends the message that this drug will help you solve your problems, when often it just creates problems,” Andrew Parrott, a psychologist at Swansea University in Wales, told the New York Times. “This is a messy drug we know can do damage.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.